(Q43865009)

27 November 2017

title

Induction of hepatic and presystemic metabolism of antipyrine in the mice: rifampicin versus rifabutin (English)

1 reference

27 November 2017

1 reference

X G Liu

1

1 reference

27 November 2017

P K Narang

series ordinal

2

1 reference

27 November 2017

R C Li

series ordinal

3

1 reference

27 November 2017

publication date

1 October 2001

1 reference

European Journal of Drug Metabolism and Pharmacokinetics

27 November 2017

published in

1 reference

27 November 2017

volume

26

1 reference

27 November 2017

issue

4

1 reference

27 November 2017

page(s)

209-213

1 reference

https://scigraph.springernature.com/pub.10.1007/bf03226373

27 November 2017

exact match

0 references

cites work

Clinical pharmacokinetics of rifabutin.

1 reference

https://api.crossref.org/works/10.1007%2FBF03226373

Induction and autoinduction properties of rifamycin derivatives: a review of animal and human studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03226373

Inducing properties of rifabutin, and effects on the pharmacokinetics and metabolism of concomitant drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03226373

A model based assessment of redistribution dependent elimination and bioavailability of rifabutin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03226373

Assay of Antipyrine and Its Primary Metabolites in Plasma, Saliva and Urine by High-Performance Liquid Chromatography and Some Preliminary Results in Man

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03226373

Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03226373

The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03226373

Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03226373

Pharmacokinetics of oral and intravenous rifampicin during chronic administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03226373

Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin

21 January 2018

1 reference

12 December 2020

THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE

1 reference

12 December 2020

Assessment of presystemic factors on the oral bioavailability of rifampicin following multiple dosing

1 reference

12 December 2020

Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers

1 reference

12 December 2020

The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism

1 reference

12 December 2020

Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction

1 reference

12 December 2020

P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs

1 reference

12 December 2020

Update on rifampin drug interactions, III.

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF03226373

1 reference

Dimensions Publication ID

27 November 2017

1005993193

0 references

1 reference